GSK delivered a mixed fourth-quarter report Wednesday, but GSK stock surged on its long-term outlook for more than $50 ...

Revenue for Arexvy and Abrysvo fell sharply year over year in the fourth quarter due to narrower U.S. guidelines for their ...

GSK was able to offset the decline thanks to a better-than-expected performance for its cancer medicines and HIV therapeutics ...

Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...

GSK Plc plans to buy back £2 billion ($2.5 billion) of shares as it raised its long-term growth outlook on optimism around ...

Clinical-stage biotechnology company Vaxxas has appointed three global vaccine experts as advisors as it progresses its ...

Pfizer's fourth quarter beat expectations on strong sales of its Covid vaccine and pill, bolstering its sales as it seeks to ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...

GSK Plc (NYSE:GSK) reported fourth-quarter sales of $10.40 billion (8.12 billion Sterling Pounds), up 1% year-over-year and ...

While the virus hasn’t made a sustained leap into humans, vaccines and treatments are being developed ahead of an outbreak.

In 2000, the Union for International Cancer Control (UICC) named Feb. | In 2000, the Union for International Cancer Control named Feb. 4 World Cancer Day, with a goal of raising awareness of cancer ...